Log In
Print
BCIQ
Print
Print this Print this
 

Velphoro, sucroferric oxyhydroxide (PA21)

  Manage Alerts
Collapse Summary General Information
Company Galenica Ltd.
DescriptionOral iron-based phosphate binder
Molecular Target
Mechanism of ActionPhosphate binder
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHyperphosphatemia
Indication DetailsTreat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis
Regulatory Designation

U.S. - Undisclosed Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis);
EU - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis);
Switzerland - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis)

Partner

Fresenius SE & Co. KGaA; Kissei Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today